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90.8%, and the success rate of the therapy with Imi-
penemfCilastatin was 71.4%.
RESULTS: Therapy with Tazobactam/Piperacillin re-
sulted in a total cost of DM 3,375 per successfully treated
patient. Therapy with ImipenemfCilastatin caused total
costs of DM 4,834 per successfully treated patient. Sensi-
tivity analyses were performed to prove the stability of
the results.
CONCLUSION: This cost-effectiveness analysis reveals
that a combination therapy with Tazobactam/Piperacillin
incurs lower total costs per successfully treated patient
than ImipenemfCilastatin.
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COLORECTAL CANCER SCREENING:
COST-EFFECTIVENESS ANALYSIS
FROM AN ITALIAN VIEWPOINT
Bona M, Fusillo M, Grossi E
Ethical Drugs Medical Department-BRACCO S,pA, Milan, Italy
Several models of colorectal cancer (CRC) screening cost-
effectiveness have been published. Most of them are
based on US costs of parameters/tests used.
OBJECTIVE: The purpose of this analysis was to provide
a model to compare several screening programs using
cost data related on Italian reimbursement system, both
for ambulatorial and for hospital services.
METHODS: Four screening programs were assessed in
comparison with nonscreening: annual fecal occult blood
test alone (FOBT), flexible sigmoidoscopy every five
years (FS), FOBT and FS combined, and one-time colono-
scopy (CO). The analysis was carried out by considering
a 10-year screening period. Effectiveness data were de-
rived from recent literature; cost-effectiveness was de-
fined as "cost per cancer prevented" (CCP) and "cost per
cancer death prevented" (CCDP). Computer analysis was
performed using algebraic formula. Data robustness was
tested with sensitivity analysis of main variables: patient
compliance, cost of cancer care, and cost of CO compli-
cation. Maximization analysis was carried out on a risk
population (selected screening).
RESULTS: CO had the greatest impact on CRC mortal-
ity, followed by FS+FOBT, FS, and FOBT. CO also re-
sulted in the most cost-effective program, both for CCP
and for CCDP, followed by FOBT+ FS, FS, and FOBT for
all the compliance levels considered. Sensitivity analysis
reinforced these results. Maximization analysis amplified
both efficacy and cost-effectiveness of CO as a test for se-
lected screening.
CONCLUSION: This model, even with the limitation
linked to cost assumption problems, seems to be useful
for authorities that will organize general population CRC
screening programs.
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COST-EFFECTIVENESS OF PIPERACILLlN-
TAZOBACTAM VERSUS CEFTAZIDIME IN
PATIENTS WITH FEBRILE NEUTROPENIA
Dominguez-Gil AI, Perez MI, Santos LI, SanzAI, Rubio C2
IHospital Universitario de Salamanca, Salamanca, Spain;-Unidad
de Farmacoeconomla, Wyeth-Lederle, Madrid, Spain
OBJECTIVE: The purpose of this study was to achieve a
cost-effectiveness analysis of the alternative piperacillin-
tazobactam (PTZ) versus ceftazidime (CFZ) both used in
conjunction with amikacin, as a therapy in post-chemo-
therapy febrile neutropenia.
METHODS: Efficacy data were obtained from the two
clinical trials performed by the European Organization
for Research and Treatment of Cancer (EORTC) and the
Groupe detudc des Aplasies Febriles (GAF). A cost-effec-
tiveness analysis has been carried out using the software
Multiprograma DUE-Estudios Farmacoeconomicos. It has
considered the alternatives (PTZ and CFZ), the type of
pharmacoeconomical study (cost-effectiveness analysis),
the pathology (febrile neutropenia), the perspective of the
study (hospital), the number of patients (493 and 498, re-
spectively), and the type of case (dependent). The follow-
ing costs have been imputed to each one of the branches
of the tree decision according to the software: the acquisi-
tion cost, the preparation and administration cost, the
monitoring cost, the treatment of adverse effects, the
structural cost, and the cost of therapeutic failure.
RESULTS: The cost per unit of effectiveness was $5,250
with PTZ and $5,850 with CFZ. The incremental cost
was $1,472 per additional case prevented with PTZ in-
stead of CFZ. The sensitivity analysis carried out regard-
ing the variables: the percentage of success, the percent-
age of overinfections, and the price of the pharmaceutical
product verified the first results of the cost-effectiveness
analysis.
CONCLUSIONS: The alternative PTZ presented a better
cost-effectiveness relation to the CFZ in the treatment of
the fever and bacteriemia in neutropenic patients, offer-
ing a reduction of the cost per unit of treatment success-
ful of $635.
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COST-EFFECTIVENESS ANALYSIS OF
PIPERACILLIN-TAZOBACTAM VERSUS
IMIPENEM-CILASTATIN IN THE TREATMENT
OF INTRA-ABDOMINAL INFECTIONS
Dominguez-Gil AI, Rubio C2
I Hospital Universrtario de Salamanca,Salamanca,Spain;-Unidad
de Farmacoeconomla, Wyeth-Lederle, Madrid, Spain
OBJECTIVE: To compare the efficiency of piperacillin-
tazobactam (Pip-Taz) and imipenern-cilasratin (Imi-Cil)
in the treatment of intra-abdominal infections, through a
cost-effectiveness analysis.
METHODS: A decision analytic model was developed to
compare the costs and outcomes of both regimens. The ef-
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ficacy data was obtained from two randomised clinical tri-
als comparing Pip-Taz (4g/0.5g t.i.d.) with Imi-Cil (hig
level dose, 19/1g t.i.d.; low level dose, 0.5g/0.5g t.i.d., re-
spectively). Information on treatment patterns and re-
sources used was obtained from five physicians in Spain
with experience in treating this condition. Prices or unit
costs were obtained from a wide range of sources including
published articles and government publications. All prices
are presented in 1995 local currency (Pts). The robustness
of the results was tested using a sensitivity analysis.
RESULTS: The efficacy rate (obtained from the analysis
of intention-to-treat patients with clinical success) of Pip-
Taz was higher (+12.5%) than low-level doses and equal
(+4.0%) to high-level doses of Imi-Cil. The incremental
costs in the Pip-Taz group were -81,651 Pts (average
cost: 543,12 Pts vs. 624,773 Pts) and -33,217 Pts
(487,698 Pts vs, 520,915 Pts) in comparison with high-
and low-level doses of Imi-Cil, respectively. According to
the incremental cost-effectiveness analysis, the Pip-Taw
treatment would result in a saving per every additional
patient with clinical success of 2,041,275 Pts and
265,736 Pts versus high and low doses of Imi-Cil, respec-
tively. However, in the hypothetical case that the Imi-
Cil's clinical efficacy was higher than the Pip-Taz effi-
cacy, the former treatment would provide savings.
CONCLUSIONS: This model shows that Pip-Taz clinical
efficacy is higher or equal to Imi-Cil, and in that case,
Pip-Taw would prove to be more cost-effective than Imi-
Cil in the treatment of intra-abdominal infections.
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USING A PNEUMONIA-SPECIFIC SEVERITY OF
ILLNESS MODEL IN ASSESSING VARIATION IN
HOSPITAL LENGTH OF STAY FOR COMMUNITY-
ACQUIRED PNEUMONIA PATIENTS
Tan H, Koeller J
University of Texas at Austin and Health Science Center in San
Antonio, TX, USA
OBJECTIVE: To assess variations in hospital length of
stay for community-acquired pneumonia patients, adjusted
for severity of illness using a pneumonia-specific model as
described by Fine et al. in the N Engl J Med 1997;336:
243-50.
METHODS: All patients admitted to University Hospi-
tal, San Antonio, during January-December 1996 with a
primary ICD-9CM diagnosis of 486 (pneumonia with no
organism specified) were evaluated retrospectively via
chart review. Patient demographics data, clinical find-
ings, hospital resource utilization such as length of stay,
length of antibiotic therapy, and hospital mortality were
collected. Patients were stratified into five risk classes.
RESULTS: A total of 187 patients was evaluated. There
were (36, 60, 42, 40, 9) patients in risk classes (I, II, III,
IV, V) . Hospital length of stay for patients in classes (I,
II, III, IV, V) were in order LOS£3 days (5, 13, 12, 3, 2),
LOS 4-7 days (24, 39, 20,18,1), and LOS >7 days (7, 8,
10, 19, 6), respectively. Average length of hospital stay
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was (6.6, 5.1, 6.2, 8.1, 9.6) days in classes I-V, respec-
tively, Anova P < 0.0026.
CONCLUSION: Variations exist in hospital LOS among
the five groups. 81% (78 patients in I and II combined)
were treated >3 days, and 71 % (30 patients in class III)
were treated >3 days. These low to moderate risk classes
(I, II, III) could be a target for reduced LOS, quality assur-
ance, and cost-effectiveness program. These differences in
LOS could be attributed to other unmeasured patient, phy-
sician, or hospital related factor and its process of care.
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EPOETIN ALFA ADMINISTERED TO ACADEMIC
HEALTH CENTER DIALYSIS PATIENTS:
COMPARISON TO HCFA BILLING RECORDS
Chen C. Danekas L, Matuszewski K. Vlasses PH
University HealthSystem Consortium, Oak Brook, IL, USA
Epoetin alpha (Epo) for use in dialysis patients represents
a substantial expenditure for academic medical centers.
OBJECTIVE: The purpose of this study was to evaluate
the efficiency and accuracy of Epo billing and reimburse-
ment systems administered and dispensed in 8 geographi-
cally distributed academic health centers.
METHODS: A retrospective chart review was performed
for 604 patients across the 8 centers, during the third or
fourth quarter of 1989 or the third quarter of years 1990
through 1993. Data collected included HCFA provider
number, Medicare number, quantity of Epo prescribed,
quantity of Epo recorded as administered for home dialy-
sis, number of doses of Epo not administered as pre-
scribed, reason for missing dose, available hemoglobin and
hematocrit values, and relevant information to explain
skipped dialysis treatments. The number of units adminis-
tered or dispensed for home use was matched to an ab-
stract of the HCFA reimbursement files for comparison.
RESULTS: Approximately 18 % of the total Epo actually
administered and/or dispensed during the course of the
study was not represented in the HCFA reimbursement
data. This ranged from 2% to 45% in the different cen-
ters. The total volume of Epo administered or dispensed
per center was not related to the percentage of under-
representation in the HCFA reimbursement files.
CONCLUSION: Epo administered and/or dispensed to
Medicare primary dialysis outpatients was under-repre-
sented in HCFA reimbursement data. As a result, institu-
tions may be experiencing a significant loss of reimburse-
ment. The exact reasons for this discrepancy are unclear.
Institutions should evaluate their Epo reporting/billing
policies and procedures to potentially increase revenue re-
covery they are due.
